Collegium Pharmaceutical, Inc.
COLL
$34.87
-$0.82-2.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.88% | 23.62% | 26.34% | 22.61% | 17.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.88% | 23.62% | 26.34% | 22.61% | 17.17% |
| Cost of Revenue | 0.21% | 4.07% | 12.07% | 11.22% | 9.02% |
| Gross Profit | 22.81% | 26.60% | 28.53% | 24.42% | 18.49% |
| SG&A Expenses | 33.96% | 53.75% | 73.79% | 66.00% | 46.50% |
| Depreciation & Amortization | 19.13% | 34.23% | 53.72% | 48.16% | 30.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.39% | 36.67% | 53.27% | 47.49% | 32.30% |
| Operating Income | 12.83% | -4.62% | -20.86% | -21.87% | -11.29% |
| Income Before Tax | 66.34% | -6.04% | -36.84% | -62.47% | -49.91% |
| Income Tax Expenses | 57.21% | 1.26% | -43.15% | -59.52% | -42.18% |
| Earnings from Continuing Operations | 70.75% | -9.13% | -34.03% | -63.69% | -52.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.75% | -9.13% | -34.03% | -63.69% | -52.95% |
| EBIT | 12.83% | -4.62% | -20.86% | -21.87% | -11.29% |
| EBITDA | 15.77% | 12.93% | 8.93% | 6.47% | 6.31% |
| EPS Basic | 73.62% | -7.25% | -32.79% | -63.00% | -51.97% |
| Normalized Basic EPS | 23.70% | -12.76% | -40.14% | -40.32% | -17.50% |
| EPS Diluted | 38.92% | -7.27% | -33.62% | -61.44% | -51.56% |
| Normalized Diluted EPS | 21.78% | -11.66% | -38.55% | -38.46% | -15.27% |
| Average Basic Shares Outstanding | -1.12% | -1.76% | -1.60% | -2.19% | -3.33% |
| Average Diluted Shares Outstanding | 3.36% | -6.58% | -7.23% | -7.85% | -8.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |